Portolan Capital Management LLC Has $8.78 Million Stake in Royalty Pharma plc (NASDAQ:RPRX)

Portolan Capital Management LLC raised its stake in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 101.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 344,185 shares of the biopharmaceutical company's stock after acquiring an additional 173,721 shares during the period. Portolan Capital Management LLC owned 0.06% of Royalty Pharma worth $8,780,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in the company. Keene & Associates Inc. grew its stake in Royalty Pharma by 1.9% during the 4th quarter. Keene & Associates Inc. now owns 19,420 shares of the biopharmaceutical company's stock worth $495,000 after buying an additional 370 shares during the last quarter. National Bank of Canada FI raised its position in Royalty Pharma by 21.8% in the 4th quarter. National Bank of Canada FI now owns 2,074 shares of the biopharmaceutical company's stock valued at $53,000 after purchasing an additional 371 shares during the last quarter. Blue Trust Inc. boosted its stake in Royalty Pharma by 31.3% during the 4th quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 376 shares during the period. Sanctuary Advisors LLC grew its position in Royalty Pharma by 0.9% during the 4th quarter. Sanctuary Advisors LLC now owns 41,854 shares of the biopharmaceutical company's stock worth $1,068,000 after purchasing an additional 388 shares during the last quarter. Finally, Arizona State Retirement System increased its stake in Royalty Pharma by 0.5% in the fourth quarter. Arizona State Retirement System now owns 110,637 shares of the biopharmaceutical company's stock valued at $2,822,000 after purchasing an additional 537 shares during the period. Hedge funds and other institutional investors own 54.35% of the company's stock.

Royalty Pharma Stock Performance

RPRX traded up $0.32 on Friday, hitting $32.51. The company had a trading volume of 2,537,288 shares, compared to its average volume of 3,248,518. The company's fifty day moving average price is $32.56 and its 200 day moving average price is $29.25. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. Royalty Pharma plc has a 1-year low of $24.05 and a 1-year high of $34.20. The stock has a market cap of $18.74 billion, a price-to-earnings ratio of 22.42, a price-to-earnings-growth ratio of 2.31 and a beta of 0.50.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. Equities analysts predict that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. TD Cowen raised shares of Royalty Pharma to a "strong-buy" rating in a report on Tuesday, December 24th. Citigroup reaffirmed a "buy" rating on shares of Royalty Pharma in a research report on Friday, March 28th. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Royalty Pharma currently has a consensus rating of "Buy" and an average target price of $42.50.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.